Request Sample Inquiry
Biosimilars Market

Biosimilars Market

Biosimilars Market - Global Industry Assessment & Forecast

img
Biotechnology and Life Sciences
Number Of Pages # Pages:

155

Base Year:

2022

Date

Feb - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1279

Segments Covered
  • By Product Class By Product Class Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-Inflammatory Agents, Other Product Classes
  • By Application By Application Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, Other Applications
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 35.14 Billion
Revenue 2030Revenue 2030: USD 216.32 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 25.50%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): Europe
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Biosimilars Market - Segment Analysis
    1. Overview
    2. Global Biosimilars Market, 2016 - 2028 (USD Million)
    3. Global Biosimilars Market - by Product Class
      1. By Monoclonal Antibodies
      2. By Recombinant Hormones
      3. By Immunomodulators
      4. By Anti-Inflammatory Agents
      5. By Other Product Classes
    4. Global Biosimilars Market - by Application
      1. By Blood Disorders
      2. By Growth Hormonal Deficiency
      3. By Chronic and Autoimmune Disorders
      4. By Oncology
      5. By Other Applications
    5. Global Biosimilars Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    6. Market comparative analysis
  4. North America Biosimilars Market - Segment Analysis
    1. Overview
    2. North America Biosimilars Market, 2016 - 2028 (USD Million)
    3. North America Biosimilars Market, by Product Class
      1. By Monoclonal Antibodies
      2. By Recombinant Hormones
      3. By Immunomodulators
      4. By Anti-Inflammatory Agents
      5. By Other Product Classes
    4. North America Biosimilars Market, by Application
      1. By Blood Disorders
      2. By Growth Hormonal Deficiency
      3. By Chronic and Autoimmune Disorders
      4. By Oncology
      5. By Other Applications
    5. North America Biosimilars Market, by Country
      1. U.S.
        1. U.S. Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. U.S. Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      2. Canada
        1. Canada Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Canada Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      3. Mexico
        1. Mexico Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Mexico Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
  5. Europe Biosimilars Market - Segment Analysis
    1. Overview
    2. Europe Biosimilars Market, 2016 - 2028 (USD Million)
    3. Europe Biosimilars Market, by Product Class
      1. By Monoclonal Antibodies
      2. By Recombinant Hormones
      3. By Immunomodulators
      4. By Anti-Inflammatory Agents
      5. By Other Product Classes
    4. Europe Biosimilars Market, by Application
      1. By Blood Disorders
      2. By Growth Hormonal Deficiency
      3. By Chronic and Autoimmune Disorders
      4. By Oncology
      5. By Other Applications
    5. Europe Biosimilars Market, by Country
      1. Germany
        1. Germany Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Germany Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      2. UK
        1. UK Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. UK Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      3. France
        1. France Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. France Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      4. Spain
        1. Spain Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Spain Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      5. Italy
        1. Italy Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Italy Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      6. BENELUX
        1. BENELUX Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. BENELUX Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      7. Rest of Europe
        1. Rest Of Europe Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Rest Of Europe Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
  6. Asia Pacific Biosimilars Market - Segment Analysis
    1. Overview
    2. Asia Pacific Biosimilars Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Biosimilars Market, by Product Class
      1. By Monoclonal Antibodies
      2. By Recombinant Hormones
      3. By Immunomodulators
      4. By Anti-Inflammatory Agents
      5. By Other Product Classes
    4. Asia Pacific Biosimilars Market, by Application
      1. By Blood Disorders
      2. By Growth Hormonal Deficiency
      3. By Chronic and Autoimmune Disorders
      4. By Oncology
      5. By Other Applications
    5. Asia Pacific Biosimilars Market, by Country
      1. China
        1. China Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. China Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      2. Japan
        1. Japan Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Japan Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      3. India
        1. India Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. India Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      4. South Korea
        1. South Korea Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. South Korea Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      5. South East Asia
        1. South East Asia Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. South East Asia Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Rest of Asia Pacific Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
  7. Latin America Biosimilars Market - Segment Analysis
    1. Overview
    2. Latin America Biosimilars Market, 2016 - 2028 (USD Million)
    3. Latin America Biosimilars Market, by Product Class
      1. By Monoclonal Antibodies
      2. By Recombinant Hormones
      3. By Immunomodulators
      4. By Anti-Inflammatory Agents
      5. By Other Product Classes
    4. Latin America Biosimilars Market, by Application
      1. By Blood Disorders
      2. By Growth Hormonal Deficiency
      3. By Chronic and Autoimmune Disorders
      4. By Oncology
      5. By Other Applications
    5. Latin America Biosimilars Market, by Country
      1. Brazil
        1. Brazil Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Brazil Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      2. Argentina
        1. Argentina Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Argentina Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      3. Rest of Latin America
        1. Rest of Latin America Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Rest of Latin America Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
  8. Middle East & Africa Biosimilars Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Biosimilars Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Biosimilars Market, by Product Class
      1. By Monoclonal Antibodies
      2. By Recombinant Hormones
      3. By Immunomodulators
      4. By Anti-Inflammatory Agents
      5. By Other Product Classes
    4. Middle East & Africa Biosimilars Market, by Application
      1. By Blood Disorders
      2. By Growth Hormonal Deficiency
      3. By Chronic and Autoimmune Disorders
      4. By Oncology
      5. By Other Applications
    5. Middle East & Africa Biosimilars Market, by Country
      1. GCC Countries
        1. GCC Countries Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. GCC Countries Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      2. South Africa
        1. South Africa Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. South Africa Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Biosimilars Market, By Product Class
          1. By Monoclonal Antibodies
          2. By Recombinant Hormones
          3. By Immunomodulators
          4. By Anti-Inflammatory Agents
          5. By Other Product Classes
        2. Rest of Middle East & Africa Biosimilars Market, By Application
          1. By Blood Disorders
          2. By Growth Hormonal Deficiency
          3. By Chronic and Autoimmune Disorders
          4. By Oncology
          5. By Other Applications
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. F. Hoffmann-La Roche Ltd. (US)
    2. Sandoz International GmbH (Switzerland)
    3. Dr. Reddy’s Laboratories Ltd. (India)
    4. Teva Pharmaceutical Industries Ltd. (Israel)
    5. Pfizer Inc. (US)
    6. Samsung Bioepis (South Korea)
    7. Biocon (India)
    8. and Mylan N.V (US).
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 09-Feb-2022
Biosimilars Market to Reach Valuation of USD 103.94 Billion by 2028 - Increasing Regulations Favoring Biosimilars Adoption is Driving the Market
FAQ
Frequently Asked Question

  • The global Biosimilars valued at USD 35.14 Billion in 2022 and is expected to reach USD 216.32 Billion in 2030 growing at a CAGR of 25.50%.

  • The prominent players in the market are F. Hoffmann-La Roche Ltd. (US), Sandoz International GmbH (Switzerland), Dr. Reddy’s Laboratories Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Samsung Bioepis (South Korea), Biocon (India), and Mylan N.V (US)..

  • The market is project to grow at a CAGR of 25.50% between 2023 and 2030.

  • The driving factors of the Biosimilars include

    • Increasing Demand for Biosimilar Drugs due to their Cost-Effectiveness

  • Europe was the leading regional segment of the Biosimilars in 2022.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy